NOVN - New VP... Trend Continues

2019年9月5日

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.

SHORT INTEREST
837.72K 08/15/19

P/E Current
-4.17

P/E Ratio (with extraordinary items)
-2.14

Average Recommendation: OVERWEIGHT

Average Target Price: 6.00